admin

Medality Medical Commences Clinical Trial for Type 2 Diabetes

MIDLAND PARK, NJ – September 16, 2019 – Medality Medical LLC (“Medality” or the “Company”), a U.S.-based medical technology company, announced that it has received Institutional Review Board (IRB) approval from the University of Texas Health Science Center at San Antonio to commence human trials. Patient recruitment is currently underway for the first in-human clinical trial […]

Medality Medical Commences Clinical Trial for Type 2 Diabetes Read More »

Medality Medical LLC Named Company Most Likely to Succeed at the 2019 NJ Tech Council Venture Conference

(Midland Park, NJ – April 24, 2019) Medality Medical LLC has been named “2019’s Company Most Likely to Succeed” by the NJ Tech Council at the NJ Tech Council Venture Conference held on April 11, 2019 at the Wellness & Events Center at the New Jersey Institute of Technology in Newark. Mediality Medical was selected

Medality Medical LLC Named Company Most Likely to Succeed at the 2019 NJ Tech Council Venture Conference Read More »

Medality Medical™ LLC Appoints Laurence Hirsch, MD, FACP, as Chief Medical Advisor

(Midland Park, N.J. – February 27, 2019) Medality Medical LLC, a U.S.-based medical technology company, announced today that Laurence (Larry) Hirsch, MD, FACP, has been named Chief Medical Advisor. With nearly four decades of extensive clinical and professional experience in diabetes research and management, Dr. Hirsch will lead the development and implementation of Medality Medical’s

Medality Medical™ LLC Appoints Laurence Hirsch, MD, FACP, as Chief Medical Advisor Read More »

Medality Medical™ LLC Receives FDA Investigational Device Exemption Approval for Reversal of Type 2 Diabetes Clinical Trial

MIDLAND PARK, NJ – February 14,2019 – Medality Medical LLC, a U.S.-based medical technology company, announced that it has received U.S. Food & Drug Administration (FDA) Investigational Device Exemption (IDE”) approval to undertake a clinical trial of its patented proprietary medical device and surgical procedure designed to reverse type 2 diabetes and associated obesity. According

Medality Medical™ LLC Receives FDA Investigational Device Exemption Approval for Reversal of Type 2 Diabetes Clinical Trial Read More »

Andrew Technologies Announces World’s First Successful Mesenteric Fat Extraction, a Long-Awaited Breakthrough for Potential Reversal of Diabetes

TUSTIN, Calif., October 17, 2016 – Andrew Technologies, LLC today announced that for the first time in the history of surgery, it has safely extracted mesenteric visceral fat in mammals, using the company’s proprietary Tissue Liquefaction Technology™ (TLT). These visceral lipectomy successes mark a positive start to the company’s proof of concept for a procedure

Andrew Technologies Announces World’s First Successful Mesenteric Fat Extraction, a Long-Awaited Breakthrough for Potential Reversal of Diabetes Read More »

Two New Studies Demonstrate Advantages of Andrew Technologies’ HydraSolve® as the Company Heads to ASPS 2016

TUSTIN, Calif., September 19, 2016 – Andrew Technologies, LLC today announced the first published clinical study of HydraSolve for breast reconstruction and the availability of new clinical data comparing HydraSolve to suction-assisted liposuction (SAL) as it prepares to attend the American Society of Plastic Surgery (ASPS) meeting this week in Los Angeles. The HydraSolve study

Two New Studies Demonstrate Advantages of Andrew Technologies’ HydraSolve® as the Company Heads to ASPS 2016 Read More »